NCT01697722View on ClinicalTrials.gov

Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy

CompletedOBSERVATIONAL
Enrollment

815,377

Participants

Timeline

Start Date

January 31, 1991

Primary Completion Date

June 30, 2007

Study Completion Date

February 28, 2010

Conditions
Asthma
Interventions
DRUG

Extra-fine hydrofluoroalkane-beclometasone dipropionate

Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI

DRUG

ICS / LABA via separate pMDI and / or BAI inhalers

A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose

Trial Locations (1)

Unknown

General Practice Research Database, London

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Research in Real-Life Ltd

NETWORK